Skip to main content

Advertisement

Table 1 Characteristics of the studies included

From: Neuromuscular blocking agents in patients with acute respiratory distress syndrome: a summary of the current evidence from three randomized controlled trials

Characteristics Gainnier M, 2004 7 Forel JM, 2006 8 Papazian L, 2010 3
  NMBA Control NMBA Control NMBA Control
Number of centers Four   Three   Twenty  
Number of participants 28 28 18 18 177 162
Age, years 59.8 ± 17.5 61.5 ± 14.6 52.0 ± 16.0 61.0 ± 18.0 58.0 ± 16.0 58 ± 15.0
Lung injury score 2.89 ± 0.40 2.93 ± 0.42 3.0 ± 0.2 2.8 ± 0.4 --- ---
SAPS II 41.8 ± 10.4 45.4 ± 10.5 47.0 ± 15.0 49.0 ± 19.0 50.0 ± 16.0 47.0 ± 14.0
Drug used Cistracurium Placebo Cistracurium Placebo Cisatracurium Placebo
Sedation strategy Ramsay 6* Ramsay 6* Ramsay 6* Ramsay 6* Ramsay 6* Ramsay 6*
Assessment of blockade TOF None TOF None None None
Maximal time to randomization, hours 36 36 48 48 48 48
Time with NMBA, hours 48   48   48  
Onset of ARDS, days 0.96 ± 0.79 1.14 ± 1.72 1.0 ± 0.8 1.2 ± 0.8 0.75 ± 0.41 0.62 ± 0.32
Days receiving mechanical ventilation 2.7 ± 2.6 3.4 ± 3.5 --- --- 0.91 ± 0.87 0.87 ± 0.74
Baseline PaO2 / FiO2 130 ± 34 119 ± 31 105 ± 22 125 ± 20 106.0 ± 36.0 115.0 ± 41.0**
Baseline PaCO2, mmHg 48.3 ± 9.0 47.4 ± 11.2 51.1 ± 9.9 47.2 ± 9.8 47.0 ± 11.0 47.0 ± 11.0
Baseline PEEP, cmH2O 11.1 ± 2.8 10.9 ± 2.4 13.2 ± 2.7 11.0 ± 2.7 9.2 ± 3.2 9.2 ± 3.5
Baseline VT, mL/kg 7.1 ± 1.1 7.4 ± 1.9 6.5 ± 0.7 7.0 ± 0.7 6.55 ± 1.12 6.48 ± 0.92
Baseline FiO2, % 70.2 ± 17.0 67.3 ± 15.8 80.0 ± 15.0 71.0 ± 19.0 79.0 ± 19.0 77.0 ± 22.0
Baseline Plateau pressure, cmH2O 27.1 ± 6.2 26.1 ± 4.0 27.5 ± 4.4 24.8 ± 5.7 25.0 ± 5.1 24.4 ± 4.7
Time of assessment of oxygenation, hours 120 120 120 120 168 168
Duration of mechanical ventilation, days 20.9 ± 15.0 21.2 ± 17.4 20.0 ± 11.6 18.0 ± 8.3 --- ---
Ventilator-free days at day 28, days 3.7 ± 7.2 1.7 ± 5.3 6.0 ± 8.6 5.4 ± 6.4 10.6 ± 9.7 8.5 ± 9.4**
Barotrauma, n (%) 0 (0.0) 1 (3.5) 1 (0.0) 1 (0.0) 9 (5.0) 19 (11.7)**
Critical illness neuromyopathy, n (%) 0 (0.0) 0 (0.0) 1 (5.5) 1 (5.5) 40 (35.7) 28 (36.3)
ICU mortality, n (%) 13 (46.4) 20 (71.4) 5 (27.8) 10 (55.6) 52 (29.3) 63 (38.8)
Mortality at day 28 after inclusion, n (%) 10 (37.5) 17 (60.7) --- --- 42 (23.7) 54 (33.3)**
  1. NMBA: Neuromuscular blocking agents; SAPS: Simplified acute physiology score; ARDS: Acute respiratory distress syndrome; PEEP: Positive end expiratory pressure; VT: Tidal volume; FiO2: Fraction of inspired oxygen; ICU: Intensive care unit; TOF: train-of-fours.
  2. *: Midazolam + Sufentanil.
  3. **: p ≤ 0.05.